

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	--	--	---	--

Service Category:

- | | |
|--|---|
| ☐ Anesthesia
☐ Surgery
☐ Radiology Procedures
☐ Pathology and Laboratory Procedures | ☐ Medicine Services and Procedures
☐ Evaluation and Management Services
☐ DME/Prosthetics or Supplies
☒ Other: Part B Drugs |
|--|---|

Service Description:

This document addresses the use of **Romiplostim (Nplate)**, a thrombopoietin receptor agonist, approved by the Food and Drug Administration (FDA) for the treatment of children and adults with immune thrombocytopenia, an autoimmune disorder that can cause uncontrolled bleeding if left untreated.

Background Information:

Nplate stimulates megakaryocyte proliferation and differentiation, increasing platelet production to treat thrombocytopenia in individuals with ITP who had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Immune thrombocytopenia (ITP) is also called idiopathic thrombocytopenia purpura and immune thrombocytopenia purpura, which is an acquired autoimmune disorder characterized by low platelet counts caused by autoantibodies against platelet antigens. According to the National Institutes of Health, ITP occurs in approximately 1 in every 16,000 adults, causing unusual bruising or bleeding due to an abnormally low number of platelets in the blood.

Nplate is FDA indicated for the following:

- Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.
- Adults and pediatrics (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]).

Limitations of Use per label:

- Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP.
- Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding.
- Nplate should not be used in an attempt to normalize platelet counts.

Per specialty committee consensus opinion, ongoing treatment with Nplate (romiplostim) may be used to maintain an adequate platelet count (50 – 100 X 10⁹/L) to decrease the risk of bleeding. For platelet count greater than 100,000/mm³, dose adjustments can be made using a cut-off platelet level of 100,000/mm³ as a substitute for 200,000/mm³ in the FDA dosage and administration recommendations.

The NCCN Drugs and Biologics Compendium and NCCN Clinical Practice Guideline offers a Category 2A recommendation for the treatment of individuals with lower risk MDS disease with severe or refractory thrombocytopenia using romiplostim following disease progression or no response to hypomethylating agents,

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

immunosuppressive therapy, or clinical trial. “Lower risk defined as IPSS-R (Very Low, Low, Intermediate), IPSS (Low/Intermediate-1), WPSS (Very low, low, intermediate)”. NCCN also provides a 2A recommendation for use of Nplate in chemotherapy-induced thrombocytopenia with the goal of allowing resumption of chemotherapy regimen when the benefits outweigh the risks and for the management of immunotherapy-related G3 or G4 thrombocytopenia if no response to corticosteroids after 1-2 weeks.

Definitions and Measures

- Aplastic anemia: A condition that occurs when the body stops producing enough new blood cells.
- Immune thrombocytopenia: A bleeding disorder where the blood is unable to clot, as a result of a low number of platelets or thrombocytes.
- The International Prognostic Scoring System (IPSS): IPSS is the most widely used prognostic classification system for myelodysplastic syndrome (MDS). The IPSS-R is the revised international prognostic scoring system in MDS to better predict outcomes in newly diagnosed patients. The WHO classification-based Prognostic Scoring System (WPSS) allows for dynamic estimation of prognosis at multiple time points during the course of MDS.
- Maintenance therapy: Designed to maintain a condition to prevent a relapse.

Approved Indications

- A. Patients with Immune Thrombocytopenia (ITP)
- B. Patients with Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)

Other Uses

- A. Myelodysplastic syndrome (MDS)
- B. Chemotherapy Induced Thrombocytopenia (CIT)
- C. Management of Immune Checkpoint Inhibitor-Related Toxicities

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

Medical Necessity Guidelines:

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Romiplostim (Nplate®)

- A. Criteria For Initial Approval** (*Provider must submit documentation [such as office chart notes, lab results, pathology reports, imaging studies, and any other pertinent clinical information] supporting the patient's diagnosis for the drug and confirming that the patient has met **all** approval criteria.*)

Initial requests for Nplate (romiplostim) may be approved if the following criteria are met:

- i. Individual has a diagnosis of *immune (idiopathic) thrombocytopenia (ITP)* and the following criteria are met (Label):
 - A. Documentation is provided that individual has a platelet count of less than 30 x 109/L or active bleeding (ASH, 2011; Hicks et al., 2014); **AND**
 - B. Individual has had a prior trial and insufficient response to one of the following:
 1. Corticosteroids; **OR**
 2. Immunoglobulins (for example IVIg or anti-D); **OR**
 3. Splenectomy
- OR**
- ii. Individual has a diagnosis of *Myelodysplastic Syndrome (MDS)* and the following criteria are met (NCCN 2A):
 - A. Documentation is provided that individual has a diagnosis of lower risk myelodysplastic syndrome (MDS) [Lower risk defined as IPSS-R (Very Low, Low, Intermediate), IPSS (Low/Intermediate-1), WPSS (Very low, low, intermediate)]; **AND**
 - B. Individual has severe or refractory thrombocytopenia following disease progression or no response to or relapse hypomethylating agents or immunosuppressive therapy.
- OR**
- iii. Individual has a diagnosis of *Hematopoietic Syndrome of Acute Radiation Syndrome (HS-ARS)* and the following criteria are met (Label):
 - A. Individual a diagnosis of Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS] (i.e., acute exposure to myelosuppressive doses of radiation); **AND**
 - B. Individual has suspected or confirmed exposure to radiation levels greater than 2 gray (Gy).
- OR**
- iv. Individual has a diagnosis of *Chemotherapy Induced Thrombocytopenia (CIT)* and the following criteria are met (NCCN 2A):
 - A. Individual has a diagnosis of chemotherapy-induced thrombocytopenia (CIT); **AND**
 - B. Individual meets one of the following criteria:

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

1. Individual has platelets less than 100 x 10⁹/L for at least 3 weeks following the last chemotherapy administration; **OR**
2. Individual has platelets less than 100 x 10⁹/L and there are delays in chemotherapy related to thrombocytopenia; **AND**
- C. Individual was using a cytotoxic chemotherapy agent that is known to cause thrombocytopenia; **AND**
- D. The goal of therapy is to maintain the dosing schedule and/or intensity of the chemotherapy regimen when such benefit outweighs the potential risks.

OR

- v. Initial requests for Nplate (romiplostim) *for the management of Immune Checkpoint Inhibitor-Related Toxicities (immunotherapy-related thrombocytopenia)* may be approved if the following criteria are met (NCCN 2A):
 - A. Documentation is provided that individual has a diagnosis of immunotherapy-related Grade 3 (G3) or Grade 4 (G4) thrombocytopenia (defined as platelet count 50000/mm³ or less); **AND**
 - B. Thrombocytopenia is due to immune checkpoint inhibitor therapy; **AND**
 - C. Thrombocytopenia has not responded to corticosteroid treatment after at least one (1) week of therapy.

B. Criteria For Continuation of Therapy

- i. Continuation requests for Nplate (romiplostim) for *ITP* may be approved if the following criteria are met:
 - A. Individual has a diagnosis of *ITP* and the following are met:
 1. Documentation is provided that individual has demonstrated a response to therapy as confirmed by increased platelet counts; **AND**
 2. Continuation of treatment is to maintain an adequate platelet count (50 – 100 X 10⁹/L)* to decrease the risk of bleeding.
- ii. Continuation requests for *MDS* may be approved if the following criteria are met:
 - A. Documentation is provided that individual has demonstrated a clinically significant response to therapy, such as an increase in platelet counts, decrease in bleeding events, or reduction in need for platelet transfusions.
- iii. Continuation requests for *CIT* may be approved if the following criteria are met:
 - A. Individual has a diagnosis of *CIT* and the following are met:
 1. Individual has demonstrated a response to therapy as confirmed by increased platelet counts; **AND**
 2. Continuation of treatment is to maintain an adequate platelet count (100 - 150 X 10⁹/L) to allow for the resumption of chemotherapy regimen as appropriate.
- iv. Continuation requests for Nplate (romiplostim) for *immunotherapy-related thrombocytopenia* may be approved if the following criteria are met:
 - A. Individual has a diagnosis of immunotherapy-related thrombocytopenia; **AND**
 - B. Documentation is provided that individual has demonstrated a response to therapy shown by increased platelet counts.

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

C. Authorization Duration

- i. Approval Duration for *ITP, MDS, CIT* and *immunotherapy-related thrombocytopenia*:
 - A. Initial Approval Duration: : 6 months
 - B. Reauthorization Approval Duration: 12 months
- ii. Approval Duration for HS-ARS: 1 single administration per episode

D. Conditions Not Covered

Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- i. Individual is using to normalize platelet counts;
OR
- ii. Individual is requesting for the treatment of low platelet count caused by any condition other than those conditions listed above;
OR
- iii. Individual is using in combination with eltrombopag (Alvaiz or Promacta);
OR
- iv. When the above criteria are not met and for all other indications

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

Limits or Restrictions:

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

i. N/A

B. Quantity Limitations

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Nplate (romiplostim) for injection

125 mcg, 250 mcg or 500 mcg single-dose vials

Indication	Recommended Dosage
Immune Thrombocytopenia (ITP)	1 mcg/kg once weekly as a subcutaneous injection. Adjust dose based on platelet response.
Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS])	10 mcg/kg administered once as a subcutaneous injection. Administer the dose as soon as possible after suspected or confirmed exposure to myelosuppressive doses of radiation.
Exceptions	
N/A	

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

Codes Information:

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

ICD-10 Diagnostic Codes:

Codes	Description
C93.10	Chronic myelomonocytic leukemia not having achieved remission
D46.0-D46.9	Myelodysplastic syndromes
D46.A	Refractory cytopenia with multilineage dysplasia
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts
D46.Z	Other myelodysplastic syndromes
D69.3	Immune thrombocytopenic purpura
D69.41-D69.49	Other primary thrombocytopenia
D69.59	Other secondary thrombocytopenia
D69.6	Thrombocytopenia, unspecified
T45.1X5A-T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs
T66.XXXA -T66.XXXS	Radiation sickness, unspecified, initial encounter

HCPCS Codes:

Codes	Description
J2802	Injection, romiplostim, 1 micrograms [Nplate]

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	--	--	---	--

Reference Information:

1. Amgen Inc. (2025). Nplate® (romiplostim) for injection, for subcutaneous use: Prescribing information. Revised March 2025. Accessed June 18, 2026. Available from: pi.amgen.com
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2025. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
3. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.
4. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
5. Hicks LK, Bering H, Carson KR, et al. Five hematologic tests and treatments to question. Blood. 2014; 124(24):3524-3528. Available from: <http://www.bloodjournal.org/content/bloodjournal/124/24/3524.full.pdf?sso-checked=true>. 4
6. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2025; Updated periodically.
7. NCCN Clinical Practice Guidelines in Oncology™. © 2026 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 18, 2026.
 - a. Hematopoietic Growth Factors. V3.2026. Revised December 5, 2025.
 - b. Myelodysplastic Syndromes. V3.2026. Revised January 12, 2026.
 - c. Management of Immune Checkpoint Inhibitor-Related Toxicities. Version 1.2026. Revised October 23, 2025.
8. Neunert C, Terrell DR, Arnold DM, et al. The American Society of Hematology (ASH) 2019 evidence-based practice guideline for immune thrombocytopenia. Blood Adv. 2019; 3(23):3829-3866. Available from: <https://ashpublications.org/bloodadvances/article/3/23/3829/429213/American-Society-of-Hematology-2019-guidelines-for>.
9. DeSouza S, Angelini D. Updated guidelines for immune thrombocytopenic purpura: Expanded management options. Cleveland Clinic Journal of Medicine. 2021; 88(12):664668-3866. Available from: <https://www.ccm.org/content/88/12/664#sec-1>.
10. Zheng, X Long et al. "ISTH guidelines for treatment of thrombotic thrombocytopenic purpura." Journal of thrombosis and haemostasis: JTH vol. 18,10 (2020): 2496-2502. doi:10.1111/jth.15010

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association

Utilization Management and Clinical Medical Policy

Policy Name: Romiplostim (Nplate®)	Policy Number: MP-RX-FP-63-23	Scope: ☒ MMM MA ☒ MMM MultiHealth	Origination Date: 11/30/2023 Last Review Date: 8/19/2026	Effective Date: 8/19/2026 Frequently Revision: Annual
---	---	--	---	--

Policy History:

Type of Review	Summary of Changes	P&T Approval Date	UM/CMPC Approval Date
Annual Review	Updated Background Information to include NCCN recommendation for the management of immunotherapy-related G3 or G4 thrombocytopenia. Clinical criteria reviewed: no changes. Added available dosage forms to quantity limits section. Coding reviewed: removed HCPCS code J2796 and added code J2802 for Nplate; Added ICD10 codes: C93.10, D46.A, D46.B, D46.Z, D69.6. Updated reference information and incorporated new policy template.	8/14/2026	8/19/2026
Annual Review	Add immunotherapy-related thrombocytopenia. Coding Reviewed: Added ICD-10-CM T45.1X5A-T45.1X5S, added T66.XXXD and T66.XXXS and updated description for range T66.XXXA-T66.XXXS.	9/5/2025	9/16/2025
Annual Review	Wording and formatting changes. Update Background information, Approved indications, Other uses, Clinical criteria, and Limits or restrictions (Added recommended dosage per FDA indication). Coding Reviewed: Added ICD-10-CM T66.XXXA, D69.59	2/24/2025	3/6/2025
Policy Inception	Elevance Health's Medical Policy adoption.	N/A	11/30/2023